Several studies have demonstrated that inhibition of multiple signal transduction pathways can ameliorate DUX4-induced toxicity, and thus compounds targeting these pathways have the potential to be developed into FSHD therapeutics. This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.